<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00840918</url>
  </required_header>
  <id_info>
    <org_study_id>08-861</org_study_id>
    <nct_id>NCT00840918</nct_id>
  </id_info>
  <brief_title>Intravenous Lidocaine and Postoperative Outcomes After Cardiac Surgery</brief_title>
  <official_title>The Effect of Perioperative Intravenous Lidocaine on Postoperative Outcomes After Cardiac Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being done to determine if lidocaine, administered during surgery and for 24
      hours after surgery can reduce inflammation, thereby reducing the risk of atrial fibrillation
      and 30 day mortality after surgery. Participants undergoing cardiac surgery will be
      randomized to receive either lidocaine or placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects undergoing cardiac surgery are randomized into one of two groups.

        -  Group 1: Intravenous Lidocaine Group

        -  Group 2: Intravenous placebo Group

      Either Lidocaine or placebo is administered throughout surgery and 24 hours after surgery.

      Patients in both groups will undergo quality of life assessments and functional recovery
      assessments post-surgery.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Problem with enrollment
  </why_stopped>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">December 15, 2014</completion_date>
  <primary_completion_date type="Actual">December 15, 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>atrial fibrillation</measure>
    <time_frame>postoperatively</time_frame>
    <description>To test the hypothesis that lidocaine infusion started at induction of anesthesia and maintained for 24 hours postoperatively will decrease the incidence of atrial fibrillation compared to an intravenous saline control.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>mortality</measure>
    <time_frame>30 days post surgery</time_frame>
    <description>To test the hypothesis that lidocaine infusion started at induction of anesthesia and maintained for 24 hours postoperatively will decrease the incidence of 30 day mortality as compared to an intravenous saline control.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">123</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravenous Lidocaine group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intravenous placebo Group - Placebo is administered intravenously throughout surgery and during the 24 hours following surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine</intervention_name>
    <description>Intravenous Lidocaine Group - Lidocaine administered intravenously throughout surgery and during the 24 hours following surgery.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo is administered intravenously throughout surgery and during the 24 hours following surgery</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-90 years old

          -  Scheduled for cardiac surgery requiring cardiopulmonary bypass

          -  Written informed consent

        Exclusion Criteria:

          -  Off-pump surgical procedures

          -  Anticipated deep hypothermic circulatory arrest

          -  Any contraindications to the proposed interventions including lidocaine allergy

          -  History of preoperative atrial fibrillation

          -  Baseline Screening revealing preexisting dementia or delirium

          -  Preoperative liver failure defined as Child-Pugh Score &gt; 6
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Grady, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Daniel I Sessler, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SAL Hospital</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujarat</state>
        <zip>380 054</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>February 10, 2009</study_first_submitted>
  <study_first_submitted_qc>February 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2009</study_first_posted>
  <last_update_submitted>March 27, 2019</last_update_submitted>
  <last_update_submitted_qc>March 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cardiac surgery</keyword>
  <keyword>Lidocaine</keyword>
  <keyword>Quality of life</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

